Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 1/20 | 0.41 |
| ▸ | MGLL | Q99685 | 2/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | BCL2 | P10415 | 1/20 | 0.38 |
| ▸ | CSF1R | P07333 | 3/20 | 0.37 |
| ▸ | FLT3 | P36888 | 3/20 | 0.37 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.37 |
| ▸ | KIT | P10721 | 2/20 | 0.37 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.37 |
| ▸ | ABL1 | P00519 | 3/20 | 0.35 |
| ▸ | GRM5 | P41594 | 3/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25345138 | 0.83 | MGLL (0.41) | MGLLABL1GRM5 | |
| SCHEMBL27211277 | 0.80 | MGLL (0.40) | MGLLCSF1RFLT3PDGFRBKIT | |
| SCHEMBL8228538 | 0.76 | DEGS1 (0.49) | GRIN2BNAMPTGSK3BDYRK1AHDAC1 | |
| SCHEMBL15879088 | 0.74 | GSK3B (0.42) | GRIN2BNAMPTGSK3BDYRK1ABCL2 | |
| SCHEMBL30031366 | 0.74 | LIPE (0.41) | NAMPT | |
| SCHEMBL25345568 | 0.74 | MGLL (0.40) | MGLLCSF1RFLT3PDGFRBKIT | |
| SCHEMBL24496178 | 0.73 | GRIN2B (0.45) | GRIN2BNAMPTGSK3BDYRK1ABCL2 | |
| SCHEMBL20899543 | 0.73 | DDB1 (0.48) | GRIN2BNAMPTGSK3BDYRK1ABCL2 | |
| SCHEMBL29648330 | 0.73 | GRIN2B (0.45) | GRIN2BNAMPTGSK3BDYRK1ABCL2 | |
| SCHEMBL29457495 | 0.73 | DDB1 (0.48) | GRIN2BNAMPTGSK3BDYRK1ABCL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11976057-B2 | MrgX2 antagonists | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-05-07 | — | — | US | disclosed |
| WO-2022073904-A1 | MRGX2 ANTAGONISTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-04-14 | — | — | WO | disclosed |
| US-20220112174-A1 | MRGX2 ANTAGONISTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11976057-B2 | MrgX2 antagonists | MRGPRX2, MRGPRX1, MRGPRX4 | GRIN2B 41/4885MGLL 2773/4885NAMPT 3838/4885 |
| US-20220112174-A1 | MRGX2 ANTAGONISTS | MRGPRX2, MRGPRX1, MRGPRX4 | GRIN2B 41/4885MGLL 2773/4885NAMPT 3838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.